Phase 3 Clinical Trials With Primary Completion Dates in December 2020
This is a list of Phase 3 trials with primary completion dates in December 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ABSCF | AB Science S.A. | 2020-12-01 | Phase 3 | NCT03761225 | Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer |
| AERI | Aerie Pharmaceuticals, Inc. | 2020-12-01 | Phase 3 | NCT03284853 | Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension |
| ATHX | Athersys, Inc. | 2020-12-01 | Phase 3 | NCT03545607 | MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study |
| AXSM | Axsome Therapeutics, Inc. | 2020-12-01 | Phase 3 | NCT02746068 | A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions |
| CBAY | CymaBay Therapeutics, Inc. | 2020-12-01 | Phase 3 | NCT03602560 | ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) |
| ERYP | ERYTECH Pharma S.A. | 2020-12-01 | Phase 3 | NCT03665441 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC |
| FOLD | Amicus Therapeutics, Inc. | 2020-12-01 | Phase 3 | NCT03729362 | PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD |
| GLYC | GlycoMimetics, Inc. | 2020-12-01 | Phase 3 | NCT03616470 | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia |
| HRTX | Heron Therapeutics, Inc. | 2020-12-01 | Phase 3 | NCT03974932 | Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen |
| LNTH | Lantheus Holdings, Inc. | 2020-12-01 | Phase 3 | NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization |
| MEDD | Medical Imaging Corp. | 2020-12-01 | Phase 3 | NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization |
| MEDD | Medical Imaging Corp. | 2020-12-01 | Phase 3 | NCT01450722 | Paclitaxel Eluting Stent in Long SFA Obstruction: A Prospective, Randomized Comparison With Bypass Surgery |
| MEDP | Medpace Holdings, Inc. | 2020-12-01 | Phase 3 | NCT03545607 | MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study |
| NEPH | Nephros, Inc. | 2020-12-01 | Phase 3 | NCT03646344 | Heme Arginate in Transplantation Study |
| OPTN | OptiNose, Inc. | 2020-12-01 | Phase 3 | NCT03781804 | Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps |
| ORPH | Orphazyme A/S | 2020-12-01 | Phase 3 | NCT03491462 | Arimoclomol in Amyotropic Lateral Sclerosis |
| OTIC | Otonomy, Inc. | 2020-12-01 | Phase 3 | NCT03664674 | Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease |
| RYTM | Rhythm Pharmaceuticals, Inc. | 2020-12-01 | Phase 3 | NCT03746522 | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity |
| TBPMF | Tetra Bio-Pharma Inc. | 2020-12-01 | Phase 3 | NCT04001010 | Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia |
| UTHR | United Therapeutics Corporation | 2020-12-01 | Phase 3 | NCT01027949 | An Open-Label Extension Trial of UT-15C SR in Subjects With Pulmonary Arterial Hypertension |
| ZGNX | Zogenix, Inc. | 2020-12-01 | Phase 3 | NCT03355209 | A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome |
| ZGNX | Zogenix, Inc. | 2020-12-01 | Phase 3 | NCT02823145 | An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome |